Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease

Autoimmunity Reviews

Volumn 14, Issue 6, 2015, Pages 479-489

  Lerner, Aaron ^a   Matthias, Torsten ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Mikroforum Ring   (Germany)

Author keywords

Autoimmune disease; Food additive; Industry; Intestine; Permeability; Tight junction

Indexed keywords

CARBOHYDRATE; EMULSIFYING AGENT; FOOD ADDITIVE; GLUTEN; NANOPARTICLE; ORGANIC SOLVENT; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SODIUM CHLORIDE; AUTOANTIGEN;

AUTOIMMUNE DISEASE; CELIAC DISEASE; EPIGENETICS; FOOD INDUSTRY; HUMAN; IMMUNOSTIMULATION; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE MUCOSA PERMEABILITY; MOLECULAR MIMICRY; REVIEW; RHEUMATIC DISEASE; SODIUM INTAKE; SUGAR INTAKE; TIGHT JUNCTION; ANIMAL; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; PERMEABILITY;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; FOOD ADDITIVES; HUMANS; INTESTINAL MUCOSA; PERMEABILITY; TIGHT JUNCTIONS;

EID: 84933673955     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.01.009     Document Type: Review

References (118)

1. Parks C.G., Miller F.W., Pollard K.M., Selmi C., Germolec D., Joyce K., et al. Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. Int J Mol Sci 2014, 15:14269-14297.
2. Selmi C. The worldwide gradient of autoimmune conditions. Autoimmun Rev 2010, 9:A247-A250.
3. Okada H., Kuhn C., Feillet H., Bach J.F. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol 2010, 160:1-9.
4. Rees F., Doherty M., Grainge M., Davenport G., Lanyon P., Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis Sep 29 2014, [Epub ahead of print]. 10.1136/annrheundis-2014-206334.
5. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54.
6. Lebwohl B., Ludvigsson J.F., Green P.H.R. The unfolding story of celiac disease risk factors. Clin Gastroenterol Hepatol 2014, 12:632-635.
7. Widdifield J., Paterson J.M., Bernatsky S., Tu K., Tomlinson G., Kuriya B., et al. The epidemiology of rheumatoid arthritis in Ontario, Canada. Arthritis Rheum 2014, 66:786-793.
8. West J., Fleming K.M., Tata L.J., Card T.R., Crooks C.J. Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study. Am J Gastroenterol 2014, 109:757-768.
9. Malmborg P., Grahnquist L., Lindholm J., Montgomery S., Hildebrand H. Increasing incidence of paediatric inflammatory bowel disease in northern Stockholm County, 2002-2007. J Pediatr Gastroenterol Nutr 2013, 57:29-34.
10. Benchimol E.I., Guttmann A., Griffiths A.M., Rabeneck L., Mack D.R., Brill H., et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut 2009, 58:1490-1497.
11. Loftus C.G., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Tremaine W.J., Melton L.J., et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007, 13:254-261.
12. Peschken C.A., Hitchon C.A. Rising prevalence of systemic autoimmune rheumatic disease: increased awareness, increased disease or increased survival?. Arthritis Res Ther 2012, 14(Suppl. 3):A20.
13. Grønbæk L., Vilstrup H., Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol 2014, 60:612-617.
14. Försti A.K., Jokelainen J., Timonen M., Tasanen K. Increasing incidence of bullous pemphigoid in Northern Finland: a retrospective database study in Oulu University Hospital. Br J Dermatol 2014, 171:1223-1226.
15. Holmberg M., Murtonen A., Elovaara I., Sumelahti M.L. Increased female MS incidence and differences in gender-specific risk in medium- and high-risk regions in Finland from 1981-2010. Mult Scler Int 2013, 2013:182516.
16. Murai H., Yamashita N., Watanabe M., Nomura Y., Motomura M., Yoshikawa H., et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 2011, 305:97-102.
17. Koton S., Israel I.D.D.M. Registry Study Group - IIRSG. Incidence of type 1 diabetes mellitus in the 0- to 17-yr-old Israel population, 1997-2003. Pediatr Diabetes 2007, 8:60-66.
18. Newhook L.A., Grant M., Sloka S., Hoque M., Paterson A.D., Hagerty D., et al. Very high and increasing incidence of type 1 diabetes mellitus in Newfoundland and Labrador, Canada. Pediatr Diabetes 2008, 9:62-68.
19. Sipetic S., Maksimovic J., Vlajinac H., Ratkov I., Sajic S., Zdravkovic D., et al. Rising incidence of type 1 diabetes in Belgrade children aged 0-14 years in the period from 1982 to 2005. J Endocrinol Invest 2013, 36:307-312.
20. Zaccarelli-Marino M.A. Chronic autoimmune thyroiditis in industrial areas in Brazil: a 15-year survey. J Clin Immunol 2012, 32:1012-1018.
21. Patterson C.C., Gyürüs E., Rosenbauer J., Cinek O., Neu A., Schober E., et al. Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase. Diabetologia 2012, 55:2142-2147.
22. Giagheddu M., Puggioni G., Sanna G., Tamburini G., Marrosu F., Rachele M.G., et al. Epidemiological study of myasthenia gravis in Sardinia, Italy (1958-1986). Acta Neurol Scand 1989, 79:326-333.
23. Somnier F.E., Keiding N., Paulson O.B. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol 1991, 48:733-739.
24. Storm-Mathisen A. Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand 1984, 70:274-284.
25. Rubio-Tapia A., Kyle R.A., Kaplan E.L., Johnson D.R., Page W., Erdtmann F., et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009, 137:88-93.
26. Kivity S., Agmon-Levin N., Blank M., Shoenfeld Y. Infections and autoimmunity-friends or foes?. Trends Immunol 2009, 30:409-414.
27. Kearney J. Food consumption trends and drivers. Philos Trans R Soc Lond B Biol Sci 2010, 365:2793-2807.
28. Manzel A., Muller D.N., Hafler D.A., Erdman S.E., Linker R.A., Kleinewietfeld M. Role of "Western diet" in inflammatory autoimmune diseases. Curr Allergy Asthma Rep 2014, 14:404.
29. Pereira R.A., Duffey K.J., Sichieri R., Popkin B.M. Sources of excessive saturated fat, trans fat and sugar consumption in Brazil: an analysis of the first Brazilian nationwide individual dietary survey. Public Health Nutr 2014, 17:113-121.
30. Monteiro C.A., Levy R.B., Claro R.M., de Castro I.R., Cannon G. Increasing consumption of ultra-processed foods and likely impact on human health: evidence from Brazil. Public Health Nutr 2011, 14:5-13.
31. Martins A.P., Levy R.B., Claro R.M., Moubarac J.C., Monteiro C.A. Increased contribution of ultra-processed food products in the Brazilian diet (1987-2009). Rev Saude Publica 2013, 47:656-665.
32. Moubarac J.C., Batal M., Martins A.P., Claro R., Levy R.B., Cannon G., et al. Processed and ultra-processed food products: consumption trends in Canada from 1938 to 2011. Can J Diet Pract Res 2014, 75:15-21.
33. Toloni M.H., Longo-Silva G., Konstantyner T., Taddei J.A. Consumption of industrialized food by infants attending child day care centers. Rev Paul Pediatr 2014, 32:37-42.
34. Baker P., Friel S. Processed foods and the nutrition transition: evidence from Asia. Obes Rev 2014, 15:564-577.
35. Brown I.J., Tzoulaki I., Candeias V., Elliott P. Salt intakes around the world: implications for public health. Int J Epidemiol 2009, 38:791-813.
36. Marrero N.M., He F.J., Whincup P., Macgregor G.A. Salt intake of children and adolescents in South London: consumption levels and dietary sources. Hypertension 2014, 63:1026-1032.
37. Sarno F., Claro R.M., Levy R.B., Bandoni D.H., Monteiro C.A. Estimated sodium intake for the Brazilian population, 2008-2009. Rev Saude Publica Jun 2013, 47(3):571-578.
38. Delahaye F. Should we eat less salt?. Arch Cardiovasc Dis 2013, 106:324-332.
39. Kralova Iva, Sjorblom Johan Surfactants used in food industry: a review. J Dispers Sci Technol 2009, 30:1363-1383.
40. http://www.rnrmarketresearch.com/food-emulsifiers-market-by-types-di-glycer.
41. http://www.worldchemicals.com/chemicals/food_additives.
42. Barragán-Martínez C., Speck-Hernández C.A., Montoya-Ortiz G., Mantilla R.D., Anaya J.M., Rojas-Villarraga A. Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis. PLoS One 2012, 7:e51506.
43. Wang Y., Zhou J., Tang Y., Wei Y., Gong H., Li X., et al. Nanocomplexation-assisted solubilization of pDNA in organic solvents for improved microencapsulation. J Colloid Interface Sci 2013, 394:573-581.
44. http://marketsandmarkets.com/Solvent-Market.
45. [Home > Topics > Crops > Wheat]. http://www.ers.usda.gov.
46. http://de.wikipedia.org/wiki/Wheat.
47. Adapted from Freedonia Group Inc World enzymes forecast for 2015 and 2020 Dec 2011.
48. Kieliszek M., Misiewicz A. Microbial transglutaminase and its application in the food industry. A review. Folia Microbiol 2014, 59:241-250.
49. Yokoyama K., Nio N., Kikuchi Y. Properties and applications of microbial transglutaminase. Appl Microbiol Biotechnol 2004, 64:447-454.
50. Miguel A.S.M., Martins-Meyer T.S., Figueiredo E.V.D.C., Bianca, Lobo B.W.P., et al. Enzymes in bakery: current and future trends. Food industry 2013, 287-321. [Chapter 14]. I. Muzzalupo (Ed.).
51. Malandain H. Transglutaminases: a meeting point for wheat allergy, celiac disease, and food safety. Eur Ann Allergy Clin Immunol 2005, 37:397-403.
52. McClements D.J., Rao J. Food-grade nanoemulsions: formulation, fabrication, properties, performance, biological fate, and potential toxicity. Crit Rev Food Sci Nutr 2011, 51:285-330.
53. Mozafari M.R., Johnson C., Hatziantoniou S., Demetzos C. Nanoliposomes and their applications in food nanotechnology. J Liposome Res 2008, 18:309-327.
54. http://pdf.marketpublishers.com/innoresearch/nano_enabled_packaging_4_food_n_beverage_industry_a_technology_industry_n_market_analysis.pdf.
55. Nanotechnology enters the global food chain http://nano.foe.org.au/node/164.
56. Jeon M.K., Klaus C., Kaemmerer E., Gassler N. Intestinal barrier: molecular pathways and modifiers. World J Gastrointest Pathophysiol 2013, 4:94-99.
57. Fasano A., Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005, 2:416-422.
58. Ballard S.T., Hunter J.H., Taylor A.E. Regulation of tight-junction permeability during nutrient absorption across the intestinal epithelium. Annu Rev Nutr 1995, 15:35-55.
59. Nusrat A., Turner J.R., Madara J.L. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol 2000, 279:G851-G857.
60. Turner J.R., Cohen D.E., Mrsny R.J., Madara J.L. Noninvasive in vivo analysis of human small intestinal paracellular absorption: regulation by Na+-glucose cotransport. Dig Dis Sci 2000, 45:2122-2126.
61. Yu Q., Wang Z., Li P., Yang Q. The effect of various absorption enhancers on tight junction in the human intestinal Caco-2 cell line. Drug Dev Ind Pharm 2013, 39:587-592.
62. Mahmud N., Weir D.G. The urban diet and Crohn's disease: is there a relationship?. Eur J Gastroenterol Hepatol 2001, 13:93-95.
63. Vojdani A. A potential link between environmental triggers and autoimmunity. Autoimmun Dis 2014, 2014:437231.
64. Kleinewietfeld M., Manzel A., Titze J., Kvakan H., Yosef N., Linker R.A., et al. Sodium chloride drives autoimmune disease by the induction of pathogenic Th17 cells. Nature 2013, 496:518-522.
65. Wada M., Tamura A., Takahashi N., Tsukita S. Loss of claudins 2 and 15 from mice causes defects in paracellular Na+ flow and nutrient transport in gut and leads to death from malnutrition. Gastroenterology 2013, 144:369-380.
66. Csáki K.F. Synthetic surfactant food additives can cause intestinal barrier dysfunction. Med Hypotheses 2011, 76:676-681.
67. llbäck N.G., Nyblom M., Carlfors J., Fagerlund-Aspenström B., Tavelin S., Glynn A.W. Do surface-active lipids in food increase the intestinal permeability to toxic substances and allergenic agents?. Med Hypotheses 2004, 63:724-730.
68. Roberts C.L., Rushworth S.L., Richman E., Rhodes J.M. Hypothesis: increased consumption of emulsifiers as an explanation for the rising incidence of Crohn's disease. J Crohns Colitis 2013, 7:338-341.
69. Traunmüller F. Etiology of Crohn's disease: do certain food additives cause intestinal inflammation by molecular mimicry of mycobacterial lipids?. Med Hypotheses 2005, 65:859-864.
70. Mine Y., Zhang J.W. Surfactants enhance the tight-junction permeability of food allergens in human intestinal epithelial Caco-2 cells. Int Arch Allergy Immunol 2003, 130:135-142.
71. Aspenström-Fagerlund B., Ring L., Aspenström P., Tallkvist J., Ilbäck N.G., Glynn A.W. Oleic acid and docosahexaenoic acid cause an increase in the paracellular absorption of hydrophilic compounds in an experimental model of human absorptive enterocytes. Toxicology 2007, 237:12-23.
72. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 2013, 70:631-659.
73. Hamid K.A., Katsumi H., Sakane T., Yamamoto A. The effects of common solubilizing agents on the intestinal membrane barrier functions and membrane toxicity in rats. Int J Pharm 2009, 379:100-108.
74. Sha X.Y., Fang X.L. Effect of self-microemulsifying system on cell tight junctions. Yao Xue Xue Bao 2006, 41:30-35.
75. Narai A., Arai S., Shimizu M. Rapid decrease in transepithelial electrical resistance of human intestinal Caco-2 cell monolayers by cytotoxic membrane perturbents. Toxicol In Vitro 1997, 11:347-354.
76. Ma T.Y., Nguyen D., Bui V., Nguyen H., Hoa N. Ethanol modulation of intestinal epithelial tight junction barrier. Am J Physiol 1999, 276:G965-G974.
77. Sheth P., Seth A., Atkinson K.J., Gheyi T., Kale G., Giorgianni F., et al. Acetaldehyde dissociates the PTP1B-E-cadherin-beta-catenin complex in Caco-2 cell monolayers by a phosphorylation-dependent mechanism. Biochem J 2007, 402:291-300.
78. Kuo Y.J., Shanbour L.L. Effects of ethanol on sodium, 3-O-methyl glucose, and L-alanine transport in the jejunum. Am J Dig Dis 1978, 23:51-56.
79. Hession R.M., Sharma V., Spiegel D.E., Tat C., Hwang D.G., Dieppa M., et al. Multiple sclerosis disease progression and paradichlorobenzene: a tale of mothballs and toilet cleaner. JAMA Neurol 2014, 71:228-232.
80. Buckman F. Paradichlorobenzene (toxin)-induced leucoencephalopathy. BMJ Case Rep 2013, 22.
81. Di Sabatino A., Vanoli A., Giuffrida P., Luinetti O., Solcia E., Corazza G.R. The function of tissue transglutaminase in celiac disease. Autoimmun Rev 2012, 11:746-753.
82. Reif S., Lerner A. Tissue transglutaminase - the key player in celiac disease: a review. Autoimmun Rev 2004, 3:40-45.
83. Lerner A., Blank M. Hypercoagulability in celiac disease-an update. Autoimmun Rev Aug 20 2014, 13:1138-1141.
84. Lerner A., Shapira Y., Agmon-Levin N., Pacht A., Ben-Ami Shor D., López Hoyos M., et al. The clinical significance of 25OH-vitamin D status in celiac disease. Crit Rev Allerg Immunol 2012, 42:322-330.
85. Lerner A., Makhoul B.F., Eliakim R. Neurological manifestations of celiac disease in children and adults. Eur Neurol J 2012, 4:15-20.
86. Heyman M., Abed J., Lebreton C., Cerf-Bensussan N. Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis. Gut 2012, 61:1355-1364.
87. Sapone A., Lammers K.M., Casolaro V., Cammarota M., Giuliano M.T., De Rosa M., et al. Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. BMC Med 2011, 9:23.
88. Jauregi-Miguel A., Fernandez-Jimenez N., Irastorza I., Plaza-Izurieta L., Vitoria J.C., Bilbao J.R. Alteration of tight junction gene expression in celiac disease. J Pediatr Gastroenterol Nutr 2014, 58:762-767.
89. Orlando A., Linsalata M., Notarnicola M., Tutino V., Russo F. Lactobacillus GG restoration of the gliadin induced epithelial barrier disruption: the role of cellular polyamines. BMC Microbiol 2014, 14:19-30.
90. Santos M., Torné J.M. Recent patents on transglutaminase production and applications: a brief review. Recent Pat Biotechnol 2009, 3:166-174.
91. Fasano A. Zonolin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev 2011, 91:151-175.
92. Li N., Neu J. Glutamine deprivation alters intestinal tight junctions via a PI3-K/Akt mediated pathway in Caco-2 cells. J Nutr 2009, 139:710-714.
93. Mullin J.M., Skrovanek S.M., Valenzano M.C. Modification of tight junction structure and permeability by nutritional means. Ann N Y Acad Sci 2009, 1165:99-112.
94. Kaufmann A., Koppel R., Widmer M. Determination of microbial transglutaminase in meat and meat products. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2012, 29:1364-1373.
95. Hu X., Ren J., Zhao M., Cui C., He P. Emulsifying properties of the transglutaminase-treated crosslinked product between peanut protein and fish (Decapterus maruadsi) protein hydrolysates. J Sci Food Agric 2011, 91:578-585.
96. Abe H., Goto M., Kamiya N. Protein lipidation catalyzed by microbial transglutaminase. Chemistry 2011, 17:14004-14008.
97. Hong G.P., Min S.G., Chin K.B. Emulsion properties of pork myofibrillar protein in combination with microbial transglutaminase and calcium alginate under various pH conditions. Meat Sci 2012, 90:185-193.
98. Xiong Y.L., Agyare K.K., Addo K. Hydrolyzed wheat gluten suppresses transglutaminase-mediated gelation but improves emulsification of pork myofibrillar protein. Meat Sci 2008, 80:535-544.
99. Fuchs S., Kutscher M., Hertel T., Winter G., Pietzsch M., Coester C. Transglutaminase: new insights into gelatin nanoparticle cross-linking. J Microencapsul 2010, 27:747-754.
100. Yew S.E., Lim T.J., Lew L.C., Bhat R., Mat-Easa A., Liong M.T. Development of a probiotic delivery system from agrowastes, soy protein isolate, and microbial transglutaminase. J Food Sci 2011, 76:H108-H115.
101. Lerner A., Matthias T. Hypothesis: increased consumption of food industry bacterial transglutaminase explains the surge in celiac disease incidence. Nutr Rev 2015, [accepted for publication].
102. Das S., Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm Sci Technol 2011, 12:62-76.
103. Saremi S., Dinarvand R., Kebriaeezadeh A., Ostad S.N., Atyabi F. Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies. Biomed Res Int 2013, 2013:150478.
104. Hsu L.W., Lee P.L., Chen C.T., Mi F.L., Juang J.H., Hwang S.M., et al. Elucidating the signaling mechanism of an epithelial tight-junction opening induced by chitosan. Biomaterials 2012, 33:6254-6263.
105. Yu S.H., Tang D.W., Hsieh H.Y., Wu W.S., Lin B.X., Chuang E.Y., et al. Nanoparticle-induced tight-junction opening for the transport of an anti-angiogenic sulfated polysaccharide across Caco-2 cell monolayers. Acta Biomater 2013, 9:7449-7459.
106. Hsu L.W., Ho Y.C., Chuang E.Y., Chen C.T., Juang J.H., Su F.Y., et al. Effects of pH on molecular mechanisms of chitosan-integrin interactions and resulting tight-junction disruptions. Biomaterials 2013, 34:784-793.
107. Lv L.Z., Tong C.Q., Yu J., Han M., Gao J.Q. Mechanism of enhanced oral absorption of hydrophilic drug incorporated in hydrophobic nanoparticles. Int J Nanomedicine 2013, 8:2709-2717.
108. Wen Z., Li G., Lin D.H., Wang J.T., Qin L.F., Guo G.P. Transport of PLGA nanoparticles across caco-2/HT29-MTX co-cultured cells. Yao Xue Xue Bao 2013, 48:1829-1835.
109. Zhang J., Zhu X., Jin Y., Shan W., Huang Y. Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles. Mol Pharm 2014, 11:1520-1532.
110. Loo Y., Grigsby C.L., Yamanaka Y.J., Chellappan M.K., Jiang X., Mao H.Q., et al. Comparative study of nanoparticle-mediated transfection in different GI epithelium co-culture models. J Control Release May 30 2012, 160(1):48-56.
111. McClements D.J. Edible lipid nanoparticles: digestion, absorption, and potential toxicity. Prog Lipid Res 2013, 52:409-423.
112. Borel T., Sabliov C.M. Nanodelivery of bioactive components for food applications: types of delivery systems, properties, and their effect on ADME profiles and toxicity of nanoparticles. Annu Rev Food Sci Technol 2014, 5:197-213.
113. Ulluwishewa D., Anderson R.C., McNabb W.C., Moughan P.J., Wells J.M., Roy N.C. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 2011, 141:769-776.
114. Selmi C., Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 2010, 9:A267-A270.
115. Thaler R., Karlic H., Rust P., Haslberger A.G. Epigenetic regulation of human buccal mucosa mitochondrial superoxide dismutase gene expression by diet. Br J Nutr 2009, 101:743-749.
116. Hino S., Nagaoka K., Nakao M. Metabolism-epigenome crosstalk in physiology and diseases. J Hum Genet 2013, 58:410-415.
117. Kessler D.A. Toward more comprehensive food labeling. N Engl J Med 2014, 37:193-195.
118. Sylvetsky A.C., Dietz W.H. Nutrient-content claims-guidance or cause for confusion?. N Engl J Med 2014, 371:195-198.